|
Dupilumab Could End of Being 'Blockbuster' Asthma Drug – Analyst (SNY) (REGN)
StreetInsider.com (subscription) Dupilumab may debut in 2018 as a treatment for skin and/or asthma conditions, Fernandez said. He observes the large market for asthma, with competition expected from the likes of AstraZenece (NYSE: AZN), GlaxoSmithKline (NYSE: GSK), and others. |
View full post on asthma – Google News